Viral Mimicry Evasion: a New Role for Oncogenic KRAS Mutations

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2024 Nov 26

PMID 39592415

Authors

Raymond Chen

Aobo He

Daniel D De Carvalho

Affiliations

Soon will be listed here.

Abstract

"Viral mimicry" refers to the induction of an innate immune response and interferon signaling by endogenous stimuli such as double-stranded RNA (dsRNA). This response has been shown to have strong cancer therapeutic potential, including by enhancing the effectiveness of immune checkpoint inhibition (ICI) therapies, and may represent a tumor suppression mechanism that needs to be overcome for malignant transformation to proceed. In a recent study, Zhou and colleagues identify KRAS, a frequently mutated oncogene, as a negative regulator of dsRNA and viral mimicry in an ICI-resistant colorectal cancer model. Oncogenic KRAS mutations downregulate the RNA-binding protein DDX60 by activating the AKT signaling pathway, which inhibits STAT3, a critical transcription factor regulating DDX60 and other interferon-stimulated genes. Overexpression of DDX60, which competitively binds to dsRNA to prevent RISC-mediated degradation, or targeting of KRAS elevated dsRNA levels, resulting in viral mimicry activation and potentiation of ICI treatment. These results establish KRAS as a promising target to sensitize immune "cold" tumors to ICI therapy and demonstrate the potential role of oncogenic mutations in viral mimicry evasion during tumorigenesis.

References

Sheng W, LaFleur M, Nguyen T, Chen S, Chakravarthy A, Conway J . LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. Cell. 2018; 174(3):549-563.e19. PMC: 6063761. DOI: 10.1016/j.cell.2018.05.052. View

Hosseini A, Lindholm H, Chen R, Mehdipour P, Marhon S, Ishak C . Retroelement decay by the exonuclease XRN1 is a viral mimicry dependency in cancer. Cell Rep. 2024; 43(2):113684. PMC: 11724374. DOI: 10.1016/j.celrep.2024.113684. View

Chen R, Ishak C, De Carvalho D . Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy and Cellular Homeostasis. Cancer Discov. 2021; 11(11):2707-2725. DOI: 10.1158/2159-8290.CD-21-0506. View

Murayama T, Nakayama J, Jiang X, Miyata K, Morris A, Cai K . Targeting DHX9 Triggers Tumor-Intrinsic Interferon Response and Replication Stress in Small Cell Lung Cancer. Cancer Discov. 2024; 14(3):468-491. PMC: 10905673. DOI: 10.1158/2159-8290.CD-23-0486. View

Lindholm H, Chen R, De Carvalho D . Endogenous retroelements as alarms for disruptions to cellular homeostasis. Trends Cancer. 2022; 9(1):55-68. DOI: 10.1016/j.trecan.2022.09.001. View

Liu H, Liang Z, Cheng S, Huang L, Li W, Zhou C . Mutant KRAS Drives Immune Evasion by Sensitizing Cytotoxic T-Cells to Activation-Induced Cell Death in Colorectal Cancer. Adv Sci (Weinh). 2023; 10(6):e2203757. PMC: 9951350. DOI: 10.1002/advs.202203757. View

Mugarza E, van Maldegem F, Boumelha J, Moore C, Rana S, Sopena M . Therapeutic KRAS inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. Sci Adv. 2022; 8(29):eabm8780. PMC: 9299537. DOI: 10.1126/sciadv.abm8780. View

Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen S . DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell. 2015; 162(5):961-73. PMC: 4843502. DOI: 10.1016/j.cell.2015.07.056. View

Mehdipour P, Marhon S, Ettayebi I, Chakravarthy A, Hosseini A, Wang Y . Epigenetic therapy induces transcription of inverted SINEs and ADAR1 dependency. Nature. 2020; 588(7836):169-173. DOI: 10.1038/s41586-020-2844-1. View

10.

Zhou Y, Zhang Y, Li M, Ming T, Zhang C, Huang C . Oncogenic KRAS drives immunosuppression of colorectal cancer by impairing DDX60-mediated dsRNA accumulation and viral mimicry. Sci Immunol. 2024; 9(100):eado8758. DOI: 10.1126/sciimmunol.ado8758. View

11.

Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J . Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017; 17(2):79-92. DOI: 10.1038/nrc.2016.126. View

12.

Chiappinelli K, Strissel P, Desrichard A, Li H, Henke C, Akman B . Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2015; 162(5):974-86. PMC: 4556003. DOI: 10.1016/j.cell.2015.07.011. View

13.

Drosten M, Barbacid M . KRAS inhibitors: going noncovalent. Mol Oncol. 2022; 16(22):3911-3915. PMC: 9718111. DOI: 10.1002/1878-0261.13341. View

14.

Zou T, Zhou M, Gupta A, Zhuang P, Fishbein A, Wei H . XRN1 deletion induces PKR-dependent cell lethality in interferon-activated cancer cells. Cell Rep. 2024; 43(2):113783. PMC: 10993914. DOI: 10.1016/j.celrep.2024.113783. View

15.

Cox A, Fesik S, Kimmelman A, Luo J, Der C . Drugging the undruggable RAS: Mission possible?. Nat Rev Drug Discov. 2014; 13(11):828-51. PMC: 4355017. DOI: 10.1038/nrd4389. View

16.

Liao W, Overman M, Boutin A, Shang X, Zhao D, Dey P . KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. 2019; 35(4):559-572.e7. PMC: 6467776. DOI: 10.1016/j.ccell.2019.02.008. View